Fate Therapeutics

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fate Therapeutics reports strong financials, advances innovative CAR cell therapies

Fate Therapeutics reported strong financial performance with a focus on advancing key programs and innovative CAR NK and CAR T-cell products.
The company faces challenges in managing costs post-collaboration termination and navigating increased research and development expenses.
Opportunities lie in advancing IND submissions, exploring novel therapy combinations, and enhancing transparency through data disclosures and collaboration.
Overall, Fate Therapeutics showcases strength in leveraging proprietary platforms for differentiated therapies and commitment to advancing next-gen CAR T-cell products.

Fate Therapeutics reports robust Q1 revenue growth and strategic focus

Fate Therapeutics reported strong Q1 revenue growth but faces challenges with workforce reduction and disclosure commitments
The company's financial position is robust, with a focus on advancing key CAR NK and CAR T-cell programs in 2023
Opportunities lie in exploring autoimmune applications, biomarker evaluation, and ADR technology superiority for future growth
Navigating FDA requirements and study design complexities remain key challenges for program advancement

Fate Therapeutics navigates revenue challenges, advances CAR cell programs

Fate Therapeutics faced revenue challenges in Q2 but maintained a strong financial position with significant cash reserves.
Progress in advancing CAR-NK and CAR-T cell programs signals potential growth opportunities in the oncology space.
Clear guidance on operating expenses and strategic IND submissions demonstrate a proactive approach to future growth.
Addressing revenue diversification, cost management, and effective clinical development will be key focus areas for sustained success.

Fate Therapeutics advances innovative cell therapies amidst financial stability

Fate Therapeutics demonstrated strong progress in product development and financial management, positioning them as a leader in innovative cell therapies.
While facing challenges in revenue dynamics and managing expenses, the company has opportunities to drive value through upcoming milestones and pioneering treatment approaches.
Clear communication, strategic partnerships, and a focus on clinical proof of concept will be crucial for Fate Therapeutics to navigate the competitive landscape and capitalize on opportunities for growth.
The company's commitment to advancing novel therapies in oncology and autoimmunity underscores their dedication to addressing unmet medical needs and shaping the future of patient care.

Fate Therapeutics reports solid financials, eyes autoimmune therapy expansion

Fate Therapeutics showcases strong financial position but faces expense challenges.
Their off-the-shelf cell therapy programs exhibit promising efficacy and safety profiles.
Opportunities lie in expanding clinical investigations and exploring autoimmune indications.
Challenges include high operating expenses and the need for therapy differentiation.

Fate Therapeutics excels in autoimmune therapy innovation amidst financial stability

Fate Therapeutics showcased strong performance in Q1 2024 with promising data from FT819 and FT522 programs in autoimmune diseases.
While facing high operating expenses, the company maintains financial stability and aims for continued growth and innovation in cellular therapy.
Challenges in differentiation and clinical translation are met with opportunities for expanded indications and novel treatment approaches in autoimmune settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fate Therapeutics, Inc. (NASDAQ:FATE ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Development Officer Conference Call Participants Jack Allen - Baird Operator Welcome to the Fate Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Fate Therapeutics (FATE) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.79 per share a year ago.

Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates

Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Chemotherapy

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023 at 5:00 PM ET to report its second quarter 2023 financial results and provide a corporate update.

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed against Fate on January 20, 2023 with a Class Period from April 2, 2020 to January 5, 2023. Our investigation concerns whether the board of directors of Fate have breached their fiduciary duties to the company. On April.

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Fate Therapeutics is a clinical-stage biotech. The company focuses on cell-derived oncology and immunology therapies.

Why Shares of Fate Therapeutics Soared This Week

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed against Fate on January 20, 2023 with a Class Period from April 2, 2020 to January 5, 2023. Our investigation concerns whether the board of directors of Fate have breached their fiduciary duties to the company. On April.

Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:

Fate Therapeutics to Present at Upcoming June Investor Conferences

Shares of off-the-shelf cell therapy concern Fate Therapeutics, Inc. have cratered 95% since reaching an all-time high in January 2021, punctuated by the termination of its Johnson & Johnson deal. The company has essentially hit the reset button, discontinuing four programs while laying off 60% of its staff.

Fate Therapeutics: The Future Remains Cloudy

FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.

FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses

Fate Therapeutics, Inc. (NASDAQ:FATE ) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Ed Dulac - Chief Financial Officer Wayne Chu - Chief Medical Officer Bob Valamehr - Chief Research and Development Officer Conference Call Participants Tazeen Ahmad - Bank of America Mara Goldstein - Mizuho Daina Graybosch - SVB Securities Andrea Tan - Goldman Sachs Matthew Biegler - Oppenheimer Operator Welcome to the Fate Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Fate Therapeutics, Inc. (FATE) Q1 2023 Earnings Call Transcript

Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large B-cell Lymphoma

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know

Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 3, 2023 at 5:00 PM ET to report its first quarter 2023 financial results and provide a corporate update.

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report?

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2023.

FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE

NEW YORK , March 22, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics, Inc.. Shareholders who purchased shares of FATE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)

LOS ANGELES, CA / ACCESSWIRE / March 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fate Therapeutics, Inc. ("Fate" or "the Company") (NASDAQ:FATE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 2, 2020 and January 5, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 22, 2023.

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Fate Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Fate Therapeutics, Inc. (“Fate” or the “Company”) (NASDAQ: FATE) securities between April 2, 2020 and January 5, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

NEW YORK , March 21, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE) alleging that the Company violated federal securities laws. Class Period: April 2, 2020 to January 5, 2023 Lead Plaintiff Deadline: March 22, 2023 No obligation or cost to you.

FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders

NEW YORK , March 20, 2023 /PRNewswire/ -- Attention Fate Therapeutics, Inc. ("Fate") (NASDAQ: FATE) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 2, 2020 and January 5, 2023. If you suffered a loss on your investment in Fate, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fate Investors of a Lead Plaintiff Deadline of March 22, 2023

NEW YORK , March 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"). A class action has already been filed.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE

BENSALEM, Pa. , March 17, 2023 /PRNewswire/ -- Law Offices of Howard G.

FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , March 17, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ: FATE). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/fate-therapeutics-loss-submission-form/?id=37348&from=4 The lawsuit seeks to recover losses for shareholders who purchased Fate between April 2, 2020 and January 5, 2023.

News for Fate Therapeutics Stock (FATE)